Janpreet Singh Bhandohal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Janpreet Singh Bhandohal has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Baldeep Kaur Mann
Division of Hospital Medicine, Department of Medicine, Kern Medical Center, Bakersfield, CA, USA
2 shared publications - Gerald Pekler
New York Medical College, Metropolitan Hospital, New York, NY, USA
1 shared publication - Jungrak Hong
New York City Health and Hospitals/Metropolitan Hospital Center, New York, NY, USA
1 shared publication - Mohammad Saeed
Internal Medicine, New York Medical College - Metropolitan Hospital Center, New York, USA
1 shared publication - Taimur Mirza
Department of Internal Medicine, New York Medical College at Metropolitan Hospital Center, 1901 First avenue, New York, NY 10029, United States
1 shared publication
Latest Publications
- Open Access
- 8 May 2020
- Published by Wiley in Cardiology Research and Practice
- Vol. 2020, 1-7
Beta Blocker Therapy in Heart Failure Patients with Active Cocaine Use: A Systematic Review
Background. Cocaine use is associated with multiple cardiovascular complications including heart failure. The use of different types of beta blockers in heart failure patients with active cocaine use is still a matter of debate. In this review, our objective is to systematically review the available literature regarding the use of beta blockers in the treatment of heart failure patients with concurrent cocaine use. Methods. PubMed, EMBASE, Web of Science, and Clinical Trials.gov were searched from inception to March 2019 using the Medical Subject Headings (MeSH) terms “cocaine”, “heart failure”, “beta blocker,” and “cardiomyopathy”. Only studies containing the outcomes of heart failure patients with active cocaine use who were treated with beta blockers were included. Results. The search resulted in 2072 articles out of which 12 were finally included in the review. A total number of participants were 1994 with a median sample size of 111. Most of the studies were retrospective in nature with Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence from 3 to 5. The main primary outcomes included readmission rates, mortality, left ventricular ejection fraction (LVEF) improvement, New York Heart Association (NYHA) functional class, and major adverse cardiovascular events (MACEs). In the studies analyzed, beta blockers were found to have either a beneficial or a neutral effect on primary outcomes in heart failure patients with active cocaine use. Conclusion. The use of beta blocker therapy appears to be safe and beneficial in heart failure patients with active cocaine use, although the evidence is not robust. Furthermore, large-scale studies are required to confirm this finding.
- 8 May 2020
- Published by Wiley in Cardiology Research and Practice
- Vol. 2020, 1-7
Open AccessBeta Blocker Therapy in Heart Failure Patients with Active Cocaine Use: A Systematic Review
Background. Cocaine use is associated with multiple cardiovascular complications including heart failure. The use of different types of beta blockers in heart failure patients with active cocaine use is still a matter of debate. In this review, our objective is to systematically review the available literature regarding the use of beta blockers in the treatment of heart failure patients with concurrent cocaine use. Methods. PubMed, EMBASE, Web of Science, and Clinical Trials.gov were searched from inception to March 2019 using the Medical Subject Headings (MeSH) terms “cocaine”, “heart failure”, “beta blocker,” and “cardiomyopathy”. Only studies containing the outcomes of heart failure patients with active cocaine use who were treated with beta blockers were included. Results. The search resulted in 2072 articles out of which 12 were finally included in the review. A total number of participants were 1994 with a median sample size of 111. Most of the studies were retrospective in nature with Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence from 3 to 5. The main primary outcomes included readmission rates, mortality, left ventricular ejection fraction (LVEF) improvement, New York Heart Association (NYHA) functional class, and major adverse cardiovascular events (MACEs). In the studies analyzed, beta blockers were found to have either a beneficial or a neutral effect on primary outcomes in heart failure patients with active cocaine use. Conclusion. The use of beta blocker therapy appears to be safe and beneficial in heart failure patients with active cocaine use, although the evidence is not robust. Furthermore, large-scale studies are required to confirm this finding.
- Open Access
- 18 December 2019
- Published by Wiley in International Journal of Endocrinology
- Vol. 2019, 1-10
An Overall Glance of Evidence Supportive of One-Hour and Two-Hour Postload Plasma Glucose Levels as Predictors of Long-Term Cardiovascular Events
This review summarizes the vast literature describing the long-term epidemiological studies with emphasis on postprandial glucose as a stronger predictor of cardiovascular complications as compared to fasting glucose and HbA1c. Many molecular studies also supported this fact by illustrating that postchallenge hyperglycemia is associated with elevated biomarkers of systemic inflammation in the plasma and thus increasing the chances of vascular damage. Large-scale studies have proved that vascular stiffness, brachial-ankle pulse-wave velocity, carotid intima thickness, and left ventricular hypertrophy have been associated with postprandial glucose as compared to fasting glucose or glycosylated hemoglobin.
- 18 December 2019
- Published by Wiley in International Journal of Endocrinology
- Vol. 2019, 1-10
Open AccessAn Overall Glance of Evidence Supportive of One-Hour and Two-Hour Postload Plasma Glucose Levels as Predictors of Long-Term Cardiovascular Events
This review summarizes the vast literature describing the long-term epidemiological studies with emphasis on postprandial glucose as a stronger predictor of cardiovascular complications as compared to fasting glucose and HbA1c. Many molecular studies also supported this fact by illustrating that postchallenge hyperglycemia is associated with elevated biomarkers of systemic inflammation in the plasma and thus increasing the chances of vascular damage. Large-scale studies have proved that vascular stiffness, brachial-ankle pulse-wave velocity, carotid intima thickness, and left ventricular hypertrophy have been associated with postprandial glucose as compared to fasting glucose or glycosylated hemoglobin.
- 1 October 2017
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 35 (10) , 1581.e1-1581.e2
BLIND OVERNIGHT: A case of fulminant idiopathic intracranial hypertension
- 1 October 2017
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 35 (10) , 1581.e1-1581.e2
BLIND OVERNIGHT: A case of fulminant idiopathic intracranial hypertension